|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: SFN |
Gene summary for SFN |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | SFN | Gene ID | 2810 |
| Gene name | stratifin | |
| Gene Alias | YWHAS | |
| Cytomap | 1p36.11 | |
| Gene Type | protein-coding | GO ID | GO:0000079 | UniProtAcc | P31947 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 2810 | SFN | GSM4909282 | Human | Breast | IDC | 1.52e-09 | 3.76e-01 | -0.0288 |
| 2810 | SFN | GSM4909286 | Human | Breast | IDC | 4.19e-09 | -4.66e-01 | 0.1081 |
| 2810 | SFN | GSM4909293 | Human | Breast | IDC | 1.13e-17 | -5.15e-01 | 0.1581 |
| 2810 | SFN | GSM4909294 | Human | Breast | IDC | 1.20e-14 | -4.63e-01 | 0.2022 |
| 2810 | SFN | GSM4909296 | Human | Breast | IDC | 1.80e-04 | 4.09e-02 | 0.1524 |
| 2810 | SFN | GSM4909297 | Human | Breast | IDC | 2.02e-11 | -4.00e-01 | 0.1517 |
| 2810 | SFN | GSM4909298 | Human | Breast | IDC | 9.50e-12 | -4.68e-01 | 0.1551 |
| 2810 | SFN | GSM4909299 | Human | Breast | IDC | 4.81e-03 | -3.18e-01 | 0.035 |
| 2810 | SFN | GSM4909301 | Human | Breast | IDC | 1.87e-24 | -5.42e-01 | 0.1577 |
| 2810 | SFN | GSM4909302 | Human | Breast | IDC | 1.42e-10 | -4.68e-01 | 0.1545 |
| 2810 | SFN | GSM4909306 | Human | Breast | IDC | 2.72e-06 | -4.56e-01 | 0.1564 |
| 2810 | SFN | GSM4909307 | Human | Breast | IDC | 1.10e-07 | -4.15e-01 | 0.1569 |
| 2810 | SFN | GSM4909308 | Human | Breast | IDC | 3.62e-06 | -4.27e-01 | 0.158 |
| 2810 | SFN | GSM4909311 | Human | Breast | IDC | 1.16e-24 | -5.28e-01 | 0.1534 |
| 2810 | SFN | GSM4909312 | Human | Breast | IDC | 9.42e-13 | -4.84e-01 | 0.1552 |
| 2810 | SFN | GSM4909319 | Human | Breast | IDC | 1.68e-19 | -3.96e-01 | 0.1563 |
| 2810 | SFN | GSM4909321 | Human | Breast | IDC | 1.09e-09 | -3.97e-01 | 0.1559 |
| 2810 | SFN | brca1 | Human | Breast | Precancer | 6.84e-47 | 9.36e-01 | -0.0338 |
| 2810 | SFN | brca2 | Human | Breast | Precancer | 3.47e-24 | 5.58e-01 | -0.024 |
| 2810 | SFN | brca3 | Human | Breast | Precancer | 5.81e-06 | 3.40e-01 | -0.0263 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| GC |  | CAG: Chronic atrophic gastritis |
| CAG with IM: Chronic atrophic gastritis with intestinal metaplasia | ||
| CSG: Chronic superficial gastritis | ||
| GC: Gastric cancer | ||
| SIM: Severe intestinal metaplasia | ||
| WIM: Wild intestinal metaplasia | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:000183614 | Cervix | HSIL_HPV | release of cytochrome c from mitochondria | 8/737 | 59/18723 | 2.08e-03 | 2.15e-02 | 8 |
| GO:005122214 | Cervix | HSIL_HPV | positive regulation of protein transport | 23/737 | 303/18723 | 2.11e-03 | 2.17e-02 | 23 |
| GO:001083713 | Cervix | HSIL_HPV | regulation of keratinocyte proliferation | 6/737 | 35/18723 | 2.23e-03 | 2.25e-02 | 6 |
| GO:001604914 | Cervix | HSIL_HPV | cell growth | 32/737 | 482/18723 | 2.87e-03 | 2.70e-02 | 32 |
| GO:000863714 | Cervix | HSIL_HPV | apoptotic mitochondrial changes | 11/737 | 107/18723 | 3.27e-03 | 2.97e-02 | 11 |
| GO:00301041 | Cervix | HSIL_HPV | water homeostasis | 8/737 | 64/18723 | 3.51e-03 | 3.15e-02 | 8 |
| GO:190495114 | Cervix | HSIL_HPV | positive regulation of establishment of protein localization | 23/737 | 319/18723 | 4.01e-03 | 3.45e-02 | 23 |
| GO:003030713 | Cervix | HSIL_HPV | positive regulation of cell growth | 14/737 | 166/18723 | 6.04e-03 | 4.75e-02 | 14 |
| GO:009719325 | Cervix | N_HPV | intrinsic apoptotic signaling pathway | 31/534 | 288/18723 | 2.39e-10 | 2.17e-07 | 31 |
| GO:005254824 | Cervix | N_HPV | regulation of endopeptidase activity | 36/534 | 432/18723 | 9.74e-09 | 1.72e-06 | 36 |
| GO:005254724 | Cervix | N_HPV | regulation of peptidase activity | 36/534 | 461/18723 | 5.15e-08 | 5.59e-06 | 36 |
| GO:004586124 | Cervix | N_HPV | negative regulation of proteolysis | 27/534 | 351/18723 | 3.27e-06 | 1.36e-04 | 27 |
| GO:001095123 | Cervix | N_HPV | negative regulation of endopeptidase activity | 21/534 | 252/18723 | 1.21e-05 | 4.05e-04 | 21 |
| GO:001046623 | Cervix | N_HPV | negative regulation of peptidase activity | 21/534 | 262/18723 | 2.18e-05 | 6.16e-04 | 21 |
| GO:005134624 | Cervix | N_HPV | negative regulation of hydrolase activity | 25/534 | 379/18723 | 9.66e-05 | 1.97e-03 | 25 |
| GO:000854423 | Cervix | N_HPV | epidermis development | 21/534 | 324/18723 | 4.32e-04 | 6.01e-03 | 21 |
| GO:200011624 | Cervix | N_HPV | regulation of cysteine-type endopeptidase activity | 17/534 | 235/18723 | 4.36e-04 | 6.01e-03 | 17 |
| GO:004358821 | Cervix | N_HPV | skin development | 18/534 | 263/18723 | 5.79e-04 | 7.67e-03 | 18 |
| GO:000863723 | Cervix | N_HPV | apoptotic mitochondrial changes | 10/534 | 107/18723 | 9.68e-04 | 1.15e-02 | 10 |
| GO:005122224 | Cervix | N_HPV | positive regulation of protein transport | 19/534 | 303/18723 | 1.18e-03 | 1.33e-02 | 19 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa041157 | Breast | IDC | p53 signaling pathway | 16/867 | 74/8465 | 2.86e-03 | 1.86e-02 | 1.39e-02 | 16 |
| hsa0411512 | Breast | IDC | p53 signaling pathway | 16/867 | 74/8465 | 2.86e-03 | 1.86e-02 | 1.39e-02 | 16 |
| hsa0411521 | Breast | DCIS | p53 signaling pathway | 16/846 | 74/8465 | 2.23e-03 | 1.47e-02 | 1.08e-02 | 16 |
| hsa0411531 | Breast | DCIS | p53 signaling pathway | 16/846 | 74/8465 | 2.23e-03 | 1.47e-02 | 1.08e-02 | 16 |
| hsa041106 | Cervix | CC | Cell cycle | 36/1267 | 157/8465 | 4.94e-03 | 1.67e-02 | 9.86e-03 | 36 |
| hsa0411013 | Cervix | CC | Cell cycle | 36/1267 | 157/8465 | 4.94e-03 | 1.67e-02 | 9.86e-03 | 36 |
| hsa0411510 | Esophagus | HGIN | p53 signaling pathway | 21/1383 | 74/8465 | 6.25e-03 | 4.25e-02 | 3.37e-02 | 21 |
| hsa0411515 | Esophagus | HGIN | p53 signaling pathway | 21/1383 | 74/8465 | 6.25e-03 | 4.25e-02 | 3.37e-02 | 21 |
| hsa0411023 | Esophagus | ESCC | Cell cycle | 126/4205 | 157/8465 | 1.34e-15 | 5.60e-14 | 2.87e-14 | 126 |
| hsa0411524 | Esophagus | ESCC | p53 signaling pathway | 65/4205 | 74/8465 | 3.88e-12 | 6.50e-11 | 3.33e-11 | 65 |
| hsa0411033 | Esophagus | ESCC | Cell cycle | 126/4205 | 157/8465 | 1.34e-15 | 5.60e-14 | 2.87e-14 | 126 |
| hsa0411534 | Esophagus | ESCC | p53 signaling pathway | 65/4205 | 74/8465 | 3.88e-12 | 6.50e-11 | 3.33e-11 | 65 |
| hsa041102 | Liver | HCC | Cell cycle | 106/4020 | 157/8465 | 2.54e-07 | 3.04e-06 | 1.69e-06 | 106 |
| hsa041156 | Liver | HCC | p53 signaling pathway | 46/4020 | 74/8465 | 7.64e-03 | 2.08e-02 | 1.16e-02 | 46 |
| hsa041103 | Liver | HCC | Cell cycle | 106/4020 | 157/8465 | 2.54e-07 | 3.04e-06 | 1.69e-06 | 106 |
| hsa0411511 | Liver | HCC | p53 signaling pathway | 46/4020 | 74/8465 | 7.64e-03 | 2.08e-02 | 1.16e-02 | 46 |
| hsa041108 | Oral cavity | OSCC | Cell cycle | 118/3704 | 157/8465 | 7.15e-16 | 2.66e-14 | 1.35e-14 | 118 |
| hsa041159 | Oral cavity | OSCC | p53 signaling pathway | 57/3704 | 74/8465 | 4.99e-09 | 5.07e-08 | 2.58e-08 | 57 |
| hsa0411015 | Oral cavity | OSCC | Cell cycle | 118/3704 | 157/8465 | 7.15e-16 | 2.66e-14 | 1.35e-14 | 118 |
| hsa0411514 | Oral cavity | OSCC | p53 signaling pathway | 57/3704 | 74/8465 | 4.99e-09 | 5.07e-08 | 2.58e-08 | 57 |
| Page: 1 2 3 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| SFN | SNV | Missense_Mutation | c.369G>T | p.Met123Ile | p.M123I | P31947 | protein_coding | deleterious_low_confidence(0) | probably_damaging(1) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| SFN | SNV | Missense_Mutation | rs753008567 | c.721N>A | p.Glu241Lys | p.E241K | P31947 | protein_coding | deleterious_low_confidence(0.03) | benign(0.369) | TCGA-C5-A1MK-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | carboplatin | PD |
| SFN | SNV | Missense_Mutation | novel | c.177G>C | p.Trp59Cys | p.W59C | P31947 | protein_coding | deleterious_low_confidence(0) | probably_damaging(1) | TCGA-VS-A953-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD |
| SFN | SNV | Missense_Mutation | c.515T>A | p.Leu172Gln | p.L172Q | P31947 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.999) | TCGA-A6-5665-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| SFN | SNV | Missense_Mutation | rs532069878 | c.289N>A | p.Asp97Asn | p.D97N | P31947 | protein_coding | tolerated_low_confidence(1) | benign(0) | TCGA-AG-4021-01 | Colorectum | rectum adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD |
| SFN | SNV | Missense_Mutation | novel | c.47C>T | p.Ala16Val | p.A16V | P31947 | protein_coding | deleterious_low_confidence(0.02) | possibly_damaging(0.899) | TCGA-AJ-A3EK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | CR |
| SFN | deletion | In_Frame_Del | novel | c.110_112delCCT | p.Ser37del | p.S37del | P31947 | protein_coding | TCGA-AJ-A3BH-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | Unknown | I/II | Unknown | Unknown | SD | ||
| SFN | SNV | Missense_Mutation | c.610N>A | p.Asp204Asn | p.D204N | P31947 | protein_coding | deleterious_low_confidence(0) | benign(0.044) | TCGA-21-5782-01 | Lung | lung squamous cell carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| SFN | SNV | Missense_Mutation | c.147G>C | p.Lys49Asn | p.K49N | P31947 | protein_coding | deleterious_low_confidence(0) | probably_damaging(1) | TCGA-60-2698-01 | Lung | lung squamous cell carcinoma | Male | <65 | I/II | Chemotherapy | mithramycin | PD | |
| SFN | SNV | Missense_Mutation | novel | c.79A>G | p.Lys27Glu | p.K27E | P31947 | protein_coding | tolerated_low_confidence(0.14) | benign(0.027) | TCGA-BA-4077-01 | Oral cavity | head & neck squamous cell carcinoma | Female | <65 | I/II | Chemotherapy | cetuximab | PD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 2810 | SFN | DRUGGABLE GENOME | IMATINIB | IMATINIB | 21962576 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |